Multiple Myeloma

Expert faculty review and share their insights and perspectives on key findings in myeloma presented at the 2021 ASH Annual Meeting.

Share

Program Content

Activities

  • Hematology 2021: Myeloma
    Key Studies in Multiple Myeloma: Independent Conference Coverage of ASH 2021
    Conference Coverage
    Text Module
    Congratulations: You achieved a completion on 04/09/2022

    Released: May 12, 2022

    Expires: May 11, 2023

Activities

Cevostamab in RRMM
Phase I Study of Cevostamab in Patients With Heavily Pretreated R/R MM: Dosing Schedule, Updated Safety and Efficacy Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

MonumenTAL-1: Talquetamab in R/R MM
Phase I MonumenTAL-1: GPCR5D x CD3 Bispecific Antibody Talquetamab in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2021

Expires: December 19, 2022

REGN5458 in R/R MM
Phase I/II Study of BCMA x CD3 Bispecific Antibody REGN5458 in R/R MM: Updated Safety and Efficacy Results
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

IBER + DEX in RRMM
Dose-Expansion Results From Phase Ib/IIa CC-220-MM-001 Trial: Iberdomide + Dexamethasone in Relapsed/Refractory MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 12, 2021

Expires: December 11, 2022

Belantamab + Len/Dex in NDMM
Phase I/II Study: Belantamab Mafodotin With Lenalidomide + Dexamethasone in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

DREAMM-9
Phase I DREAMM-9 Study of Belantamab Mafodotin + VRd in ASCT-Ineligible Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

GMMG-HD7
GMMG-HD7: Phase III Trial of Isatuximab + VRd vs VRD Alone as Induction Therapy for Newly Diagnosed, ASCT-Eligible Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

GEM2014MAIN: Ixa + LenDex
Phase III GEM2014MAIN: Maintenance With Ixazomib + Len/Dex vs Len/Dex After VRd + ASCT in Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

CARTITUDE-1: 2-Yr Update
CARTITUDE-1 Phase Ib/II Study of Ciltacabtagene Autoleucel in Patients With R/R MM: 2-Yr Update
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2021

Expires: December 15, 2022

GRIFFIN Update: Dara-R Maintenance
GRIFFIN 2-Yr Maintenance Phase Update: Dara + VRd With Dara-R Maintenance vs VRd With R Maintenance for ASCT-Eligible Patients With Newly Diagnosed MM
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 22, 2021

Expires: December 21, 2022

Venetoclax/Dara/Dex in R/R MM
Preliminary Phase I/II Results of Venetoclax/Dara/Dex vs Bortezomib/Dara/Dex in t(11;14) Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

MCARH109 CAR T-Cell Tx in R/R MM
MCARH109, a GPCRC5D-Targeted CAR T-Cell Therapy, in Relapsed/Refractory MM: A Phase I First-in-Class Trial
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 20, 2021

Expires: December 19, 2022

Final BELLINI Analysis: Venetoclax + Vd
Final Survival Analysis of BELLINI: Venetoclax or Placebo Plus Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 14, 2021

Expires: December 13, 2022

MajesTEC-1:  Teclistamab in R/R MM
Updated Results From Phase I/II MajesTEC-1 Study: Teclistamab, a BCMA x CD3 Bispecific Antibody, in Relapsed/Refractory Multiple Myeloma
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

ABBV-383 in R/R MM
BCMA x CD3 Bispecific Antibody ABBV-383 in Relapsed/Refractory Multiple Myeloma: Update of a Phase I First-in-Human Study
Conference Coverage
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2021

Expires: December 16, 2022

Faculty

cover img faculity

Shaji K. Kumar, MD

Mark and Judy Mullins Professor of Hematological Malignancies
Consultant, Division of Hematology
Professor of Medicine
Chair, Myeloma, Amyloidosis and Dysproteinemia Group
Research Chair, Division of Hematology
Mayo Clinic
Rochester, Minnesota

cover img faculity

Sagar Lonial, MD, FACP

Chair and Professor 
Department of Hematology and Medical Oncology
Anne and Bernard Gray Family Chair in Cancer
Chief Medical Officer
Winship Cancer Institute
Emory University School of Medicine
Atlanta, Georgia

Provided by

ProCE Banner

Supporters

AbbVie

AstraZeneca

Daiichi Sankyo, Inc.

GlaxoSmithKline

Incyte Corporation

Jazz Pharmaceuticals, Inc.

Merck Sharp & Dohme Corp.

Novartis Pharmaceuticals Corporation